|Bid||141.00 x 100|
|Ask||159.00 x 100|
|Day's range||154.93 - 158.15|
|52-week range||95.08 - 170.30|
|PE ratio (TTM)||199.12|
|Earnings date||21 Feb 2018|
|Forward dividend & yield||0.00 (0.00%)|
|1y target est||151.67|
Novartis: What Are the Major Growth Drivers for 2018? Novartis’s (NVS) Promacta reported sales if $255 million in 4Q17, which is a year-over-year (or YoY) rise of 43.0% on a constant currency basis. On January 4, 2018, Novartis announced that the FDA granted breakthrough therapy designation to the combination of Promacta and immunosuppressive therapy.
Ligand's (LGND) Captisol formulation technology aids the company to form partnerships with several leading healthcare companies. This in turn might drive the stock in Q4.
Ligand Pharmaceuticals Incorporated announced today plans to report fourth quarter and full year 2017 financial results on February 21, 2018. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.
Ligand Pharmaceuticals Incorporated announces it has entered into a worldwide OmniAb platform license agreement with Ferring Pharmaceuticals. Under the license, Ferring will be able to use the full OmniAb platform including OmniRat®, OmniMouse®, OmniFlic® and OmniChicken™ to discover fully human mono- and bispecific antibodies.
Ferring Pharmaceuticals announced today that it has entered into a worldwide license agreement with Ligand Pharmaceuticals to use Ligand’s OmniAb platform® to discover new human monoclonal antibodies for a range of indications. Under the agreement, Ferring will use OmniAb to accelerate development solutions for unmet patient needs in reproductive medicine and women’s health, urology and gastroenterology.
Ligand Pharmaceuticals Incorporated announces initiation of a program to develop contrast agents with reduced renal toxicity. Contrast agents are injectable solutions used during diagnostic imaging procedures.
Stocks continued to evaporate gains in afternoon trading Tuesday, while the Russell 2000 small-cap index reversed lower.
Ligand Pharmaceuticals Incorporated announces it has entered a worldwide OmniAb platform license agreement with Glenmark Pharmaceuticals. Under the license, Glenmark will be able to use the full OmniAb platform including OmniChicken™, OmniRat®, OmniMouse® and OmniFlic® to discover fully human mono- and multispecific antibodies.
Collaboration agreements announced by companies like Sangamo (SGMO) and the submission of a regulatory application for GW's Epidiolex were the key highlights this week in the biotech sector.
Ligand Pharmaceuticals Incorporated announces that its partner HanAll Biopharma successfully out-licensed antibody projects that were discovered by HanAll using Ligand’s OmniAb® antibody discovery platform.
Tesla • TSLA-Nasdaq Sector Weight • Price $317.29 on Dec. 26 by KeyBanc Capital Markets Based on our conversations last week with salespeople at 18 Tesla stores around the U.S., we believe that Model 3 deliveries are tracking to roughly 5,000 in the quarter, below our previous estimate of 15,000. Alliance Data • ADS-NYSE Overweight • Price $250.64 on Dec. 26 by First Analysis Securities The company provides integrated credit-card, marketing, and customer-loyalty and identity programs for a variety of retail brands, including Victoria’s Secret, J. Crew, Eddie Bauer, Buckle, HSN, Pottery Barn, and Pier 1 Imports.
The Medicine Company (MDCO) has signed an agreement with Melinta to sell its infectious disease unit in a cash and stock transaction.
The deal will be beneficial for both companies as it will reduce costs and bring in a strong partner for Alkermes.
AstraZeneca's (AZN) Marketing Authorisation Application for label expansion of Tagrisso has been accepted by the European Medicines Agency.
Catalyst (CPRX) reported encouraging top-line results from a phase III study for its pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome.
Spectrum (SPPI) focuses on developing pipeline candidates. The stock doubled in the last three months mainly on encouraging data from poziotinib study.
Glaxo (GSK) and partner Innoviva submit a supplemental new drug application to the FDA for label expansion of its once-daily single inhaler triple therapy, Trelegy Ellipta.
Puma (PBYI) signs a licensing deal with Specialised Therapeutics Asia to commercialize its breast cancer drug Nerlynx in Australia, New Zealand and South East Asia.
Lilly (LLY) enters into a development agreement with DexCom to integrate the latter's continuous glucose monitoring into its Connected Diabetes Ecosystem.